JP2023548605A5 - - Google Patents
Info
- Publication number
- JP2023548605A5 JP2023548605A5 JP2023527662A JP2023527662A JP2023548605A5 JP 2023548605 A5 JP2023548605 A5 JP 2023548605A5 JP 2023527662 A JP2023527662 A JP 2023527662A JP 2023527662 A JP2023527662 A JP 2023527662A JP 2023548605 A5 JP2023548605 A5 JP 2023548605A5
- Authority
- JP
- Japan
- Prior art keywords
- aforementioned
- approximately
- polymorph
- powder diffraction
- ray powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063108803P | 2020-11-02 | 2020-11-02 | |
| US63/108,803 | 2020-11-02 | ||
| US202163190107P | 2021-05-18 | 2021-05-18 | |
| US63/190,107 | 2021-05-18 | ||
| PCT/US2021/057584 WO2022094409A1 (en) | 2020-11-02 | 2021-11-01 | Crystalline forms of a deoxycytidine kinase inhibitor and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023548605A JP2023548605A (ja) | 2023-11-17 |
| JP2023548605A5 true JP2023548605A5 (https=) | 2024-10-29 |
Family
ID=81380719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023527662A Pending JP2023548605A (ja) | 2020-11-02 | 2021-11-01 | デオキシシチジンキナーゼ阻害剤の結晶形態およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20220133735A1 (https=) |
| EP (1) | EP4237421A4 (https=) |
| JP (1) | JP2023548605A (https=) |
| KR (1) | KR20230129384A (https=) |
| AU (1) | AU2021368138A1 (https=) |
| CA (1) | CA3196694A1 (https=) |
| CL (1) | CL2023001230A1 (https=) |
| MX (1) | MX2023005056A (https=) |
| PE (1) | PE20231656A1 (https=) |
| TW (1) | TW202233613A (https=) |
| WO (1) | WO2022094409A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022094409A1 (en) | 2020-11-02 | 2022-05-05 | Trethera Corporation | Crystalline forms of a deoxycytidine kinase inhibitor and uses thereof |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| US5605798A (en) | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
| EP0700521B1 (en) | 1993-05-28 | 2003-06-04 | Baylor College Of Medicine | Method and mass spectrometer for desorption and ionization of analytes |
| GB9717926D0 (en) | 1997-08-22 | 1997-10-29 | Micromass Ltd | Methods and apparatus for tandem mass spectrometry |
| JP2002502086A (ja) | 1998-01-23 | 2002-01-22 | アナリティカ オブ ブランフォード インコーポレーテッド | 表面からの質量分光測定 |
| GB0031103D0 (en) | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
| US7259175B2 (en) | 2002-02-25 | 2007-08-21 | Eli Lilly And Company | Peroxisome proliferator activated receptor modulators |
| AU2003217274A1 (en) | 2002-02-25 | 2003-09-09 | Eli Lilly And Company | Peroxisome proliferator activated receptor modulators |
| US7528160B2 (en) | 2003-01-06 | 2009-05-05 | Eli Lilly And Company | Fused heterocyclic derivatives as PPAR modulators |
| EP1937658A1 (en) | 2005-10-06 | 2008-07-02 | Sanofi-Aventis | 4-oxy-n-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals |
| US8552174B2 (en) | 2005-10-31 | 2013-10-08 | Agilent Technologies, Inc. | Solutions, methods, and processes for deprotection of polynucleotides |
| DE102006056740A1 (de) | 2006-12-01 | 2008-06-05 | Bayer Healthcare Ag | Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung |
| US8093246B2 (en) | 2006-12-14 | 2012-01-10 | Lexicon Pharmaceuticals, Inc. | O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer |
| US8093245B2 (en) | 2006-12-14 | 2012-01-10 | Lexicon Pharmaceuticals, Inc. | 4-amino-1H-pyrimidin-2-one based compounds, compositions comprising them and methods of their use |
| AU2008302703B2 (en) | 2007-09-19 | 2013-11-07 | The Regents Of The University Of California | Positron emission tomography probes for imaging immune activation and selected cancers |
| US8022216B2 (en) * | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| WO2009086303A2 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| UA107791C2 (en) | 2009-05-05 | 2015-02-25 | Dow Agrosciences Llc | Pesticidal compositions |
| US9688673B2 (en) * | 2011-03-08 | 2017-06-27 | The Regents Of The University Of California | Deoxycytidine kinase binding compounds |
| CN108685922A (zh) | 2011-09-30 | 2018-10-23 | 沃泰克斯药物股份有限公司 | 用atr抑制剂治疗胰腺癌和非小细胞肺癌 |
| EA036177B1 (ru) | 2013-08-13 | 2020-10-09 | Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния | Ингибиторы дезоксицитидинкиназы |
| US20190000850A1 (en) | 2015-02-09 | 2019-01-03 | The Regents Of The University Of California | Combination cancer therapy |
| WO2016130562A2 (en) | 2015-02-09 | 2016-08-18 | The Regents Of The University Of California | Metabolic analysis of the nucleotide de novo and salvage pathways |
| US10570124B2 (en) * | 2016-01-08 | 2020-02-25 | The Regents Of The University Of California | Deoxycytidine kinase binding compounds |
| CN117205209A (zh) | 2016-05-25 | 2023-12-12 | 新加坡保健服务集团 | 含有阿托品的水性组合物 |
| EA201992780A1 (ru) * | 2017-06-21 | 2020-06-02 | ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи | Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания |
| WO2019165073A1 (en) * | 2018-02-21 | 2019-08-29 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
| WO2022094409A1 (en) | 2020-11-02 | 2022-05-05 | Trethera Corporation | Crystalline forms of a deoxycytidine kinase inhibitor and uses thereof |
-
2021
- 2021-11-01 WO PCT/US2021/057584 patent/WO2022094409A1/en not_active Ceased
- 2021-11-01 US US17/516,420 patent/US20220133735A1/en not_active Abandoned
- 2021-11-01 PE PE2023001523A patent/PE20231656A1/es unknown
- 2021-11-01 MX MX2023005056A patent/MX2023005056A/es unknown
- 2021-11-01 KR KR1020237018688A patent/KR20230129384A/ko active Pending
- 2021-11-01 JP JP2023527662A patent/JP2023548605A/ja active Pending
- 2021-11-01 CA CA3196694A patent/CA3196694A1/en active Pending
- 2021-11-01 EP EP21887727.2A patent/EP4237421A4/en active Pending
- 2021-11-01 AU AU2021368138A patent/AU2021368138A1/en active Pending
- 2021-11-02 TW TW110140820A patent/TW202233613A/zh unknown
-
2022
- 2022-01-14 US US17/576,128 patent/US11446307B2/en active Active
-
2023
- 2023-04-27 CL CL2023001230A patent/CL2023001230A1/es unknown
-
2024
- 2024-08-23 US US18/813,917 patent/US20250049808A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023554492A5 (https=) | ||
| ES2895511T3 (es) | Compuestos de alqueno tetrasustituido y su uso | |
| JP2023548859A5 (https=) | ||
| JP2025176008A5 (https=) | ||
| JP2023522040A5 (https=) | ||
| JP6971390B2 (ja) | 重水素化ａｚｄ９２９１の結晶形、製造方法および使用 | |
| JP2024543405A (ja) | Ｗｅｅ１プロテインキナーゼ分解剤及びその使用 | |
| TWI721947B (zh) | 抗病毒化合物的固態形式 | |
| JP6894917B2 (ja) | ピリジニルアミノピリミジン誘導体のメシル酸塩の結晶形、その製造方法及びその使用 | |
| US20250281492A1 (en) | New crystalline forms of salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine -6-carboxylic acid dimethylamide | |
| JP2011513349A (ja) | Ｎ−［２−（ジエチルアミノ）エチル］−５−［（５−フルオロ−１，２−ジヒドロ−２−オキソ−３ｈ−インドール−３−イリデン）メチル］−２，４−ジメチル−１ｈ−ピロール−３−カルボキサミドの結晶形およびその製造方法 | |
| US9815847B2 (en) | Pyrimidine compounds as kinase inhibitors | |
| JP2016517426A (ja) | 置換プリン化合物の合成方法 | |
| JP2025131661A (ja) | ２－（５－（４－（２－モルホリノエトキシ）フェニル）ピリジン－２－イル）－ｎ－ベンジルアセトアミドの固体形態 | |
| JP2023548605A5 (https=) | ||
| JP2026012715A (ja) | ３－（５－フルオロベンゾフラン－３－イル）－４－（５－メチル－５Ｈ－［１，３］ジオキソロ［４，５－ｆ］インドール－７－イル）ピロール－２，５－ジオンの固体形態 | |
| JP6816036B2 (ja) | ヒストン脱アセチル化阻害剤の結晶形態 | |
| US9453011B2 (en) | Crystal form of dabrafenib mesylate and preparation method thereof | |
| WO2013065063A1 (en) | Anhydrous form of dasatinib, process for its preparation and its use | |
| WO2016196342A1 (en) | Tetrasubstituted alkene compounds and their use | |
| TW201741286A (zh) | 3-[2-丁基-1-(2-二乙基胺基-乙基)-1h-苯并咪唑-5-基]-n-羥基-丙烯醯胺之多晶型及其用途 | |
| TW202024078A (zh) | Bet溴結構域(bromodomain)抑制劑之固體形式之製備方法 | |
| TW201912646A (zh) | Parp-1抑制劑的晶型及其製備方法 | |
| WO2017020869A1 (zh) | 2-[(2r)-2-甲基-2-吡咯烷基]-1h-苯并咪唑-7-甲酰胺的晶型b及其制备方法和应用 | |
| JP2021522348A5 (https=) |